AngioDynamics, Inc. (ANGO) News
Filter ANGO News Items
ANGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANGO News Highlights
- ANGO's 30 day story count now stands at 3.
- Over the past 7 days, the trend for ANGO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ANGO are GOLD.
Latest ANGO News From Around the Web
Below are the latest news stories about Angiodynamics Inc that investors may wish to consider to help them evaluate ANGO as an investment opportunity.
AngioDynamics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceLATHAM, N.Y., February 08, 2022--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference at 10:00 a.m. ET on Tuesday, February 15, 2022. |
Riggs Asset Managment Co. Inc. Buys SPDR Gold Shares ETF, SPDR Homebuilders ETF, iShares U.S. ...Wilkes-barre, PA, based Investment company Riggs Asset Managment Co. Inc. (Current Portfolio) buys SPDR Gold Shares ETF, SPDR Homebuilders ETF, iShares U.S. |
Is This Small-Cap Medical Devices Stock a Buy?AngioDynamics managed to deliver solid revenue growth in the second quarter despite COVID-19 headwinds. |
James Clemmer Is The CEO, President & Director of AngioDynamics, Inc. (NASDAQ:ANGO) And They Just Picked Up 3.5% More SharesInvestors who take an interest in AngioDynamics, Inc. ( NASDAQ:ANGO ) should definitely note that the CEO, President... |
Where Do Hedge Funds Stand On AngioDynamics, Inc. (ANGO)?We at Insider Monkey have gone over 867 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of AngioDynamics, Inc. (NASDAQ:ANGO) based on that data. […] |
AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues TopAngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2. |
AngioDynamics EPS misses by $0.02, beats on revenueNo summary available. |
AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q2 2022 Results - Earnings Call TranscriptNo summary available. |
AngioDynamics' backlog surpasses $4 million due to labor shortage, pandemicAngio is shifting some production to a third party in Costa Rica, but the company was adamant that its manufacturing focus would stay in upstate New York. |
AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS GuidanceLATHAM, N.Y., January 06, 2022--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the second quarter of fiscal year 2022, which ended November 30, 2021. |